ABT Abbott Laboratories
Company Analysis
Latest News
🟢 Abbott is trading 4.2% up today after FDA clearance for SimpleScreen CRC blood test
Abbott is trading 4.2% up today at $108.87 after receiving FDA clearance for its SimpleScreen CRC blood test for colorectal cancer screening in average-risk...
Abbott Secures FDA Clearance for SimpleScreen CRC, a Non-Invasive Cancer Test
Abbott Laboratories received FDA clearance for its SimpleScreen CRC blood test on July 27, 2026. The diagnostic tool detects colorectal cancer in average-risk...
Justice Department Cuts Corporate Prosecutions, Prioritizing Individual Executive Accountability
The U.S. Department of Justice is reducing criminal prosecutions against corporations. Officials increasingly resolve investigations through non-prosecution...
Abbott's $23 Billion Cancer Bet Is Paying Off Faster Than Expected — But Can a Battered Stock Sustain Its Biggest Rally in Years?
Shares of Abbott Laboratories surged 10.9% to $99.04 on July 16 after the healthcare giant delivered a second-quarter earnings surprise that Wall Street didn't...
🟢 Abbott is trading 10.9% up today after Q2 earnings beat and raised full-year guidance
Abbott is trading 10.9% up now at $99.04 after reporting stronger-than-expected second-quarter 2026 results and raising its full-year outlook. • The company...
Abbott Laboratories beats second quarter 2026 estimates and raises full-year guidance on strong Medical Devices and Diagnostics growth.
Abbott Laboratories reported second-quarter sales of $12.59 billion and adjusted EPS of $1.31, exceeding analyst expectations. Results were driven by strong...
Abbott Laboratories Q2 2026 Earnings Preview: What Analysts Expect on July 16, 2026
Abbott Laboratories is expected to report second-quarter revenue of $12.52 billion and adjusted EPS of $1.28, with shares currently trading near $89.88 against...
Abbott Labs Avoids Criminal Charges, DOJ Ends Baby Formula Plant Probe
The U.S. Department of Justice (DOJ) closed its criminal investigation into Abbott Laboratories’ infant formula plant in Sturgis, Michigan. The probe followed...
🟢 ABT is trading 4% up today on Alzheimer’s blood-test licensing deal
ABT is trading 4% up at $94.11 after announcing a global licensing agreement with ALZpath to develop blood-based Alzheimer’s diagnostic tests using the pTau217...
Abbott Licenses ALZpath Tech for Alzheimer’s Blood Tests, Replacing Costly Scans
Abbott Laboratories entered a global licensing agreement with ALZpath to develop blood-based tests for Alzheimer's disease. The partnership aims to increase...
Abbott's first quarter 2026 revenue of $11.16B beat estimates, driven by 13.2% growth in Medical Devices.
Abbott reported first quarter 2026 revenue of $11.16 billion, up 7.8% year-over-year, and adjusted EPS of $1.15, reflecting 6% growth. Comparable sales grew...
Abbott Laboratories Q1 2026 Earnings Preview: What Analysts Expect on April 16, 2026
Abbott Laboratories is expected to report Q1 2026 revenue of $11.02 billion and earnings of $1.14 per share, with shares currently trading around $100.69...
Abbott CEO Purchases $2 Million in Company Stock After Price Drop
Abbott Laboratories Chairman and CEO Robert B. Ford purchased 18,800 shares of common stock. The transaction totaled approximately $2 million. Ford acquired...
Abbott Laboratories' Valuation and Margin Compression Questioned After Fiscal Year 2025 Results
Abbott Laboratories faces scrutiny over profitability and valuation following its full-year 2025 financial results. Analysis highlighted a compressed net...
Abbott Faces Supply Chain Scrutiny in India Over Codeine-Based Cough Syrup Abuse Investigation
Abbott Laboratories (ABT) is facing new regulatory uncertainty after Indian authorities launched an investigation into its supply chain, Abbott Healthcare,...
🔴 Abbott is trading 11.4% down today after Q4 revenue miss and weak Q1 guidance
ABT is trading at $106.93, down 11.4%, following disappointing fourth-quarter earnings where revenue missed consensus and Q1 2026 guidance fell short of...
🔴 Abbott is trading 6% down in pre-market ahead of Q4 earnings call
ABT is trading at $113.76 (-5.77%) in pre-market ahead of its Q4 2025 earnings conference call scheduled for 9:00 AM ET. Consensus expectations are set for...
Abbott Laboratories' Q4 FY25 adjusted EPS grew 12% driven by 10.4% organic growth in Medical Devices.
Abbott Laboratories reported Q4 2025 sales of $11.5 billion, representing organic growth of 3.0% (or 3.8% excluding COVID-19 testing), and adjusted EPS of...
Abbott Receives European Approval for Advanced Atrial Fibrillation Catheter
Abbott received CE Mark approval in Europe for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, on January 20, 2026. The device treats atrial...
FDA Finalizes Class I Recalls for Abbott Glucose Sensors; Lawsuit Filed
The FDA finalized four Class I recalls for Abbott's continuous glucose monitoring (CGM) sensors. This action follows safety concerns Abbott initially reported...